Meril Life Sciences Unveils One-Year Data from Landmark Trial
LONDON — Meril Life Sciences recently revealed the critical one-year outcomes from the pivotal LANDMARK Randomized Controlled Trial (RCT) at a prestigious structural heart conference. This groundbreaking study stands out as the first multi-center RCT, directly comparing the balloon-expandable Myval THV series with the established Sapien and Evolut THV series in patients experiencing symptomatic severe aortic stenosis.
Significant Clinical Efficacy Findings
At the one-year mark, the Myval THV series exhibited remarkable clinical efficacy, showing a composite success rate defined as freedom from all-cause mortality, strokes, and hospitalizations related to the procedure or the valve. Specifically, the outcomes were reported as 87% for the Myval THV series, closely followed by 86.9% for both the Sapien and Evolut series.
Extended Clinical Efficacy Metrics
The trial also examined extended clinical efficacy, which included measures for quality of life and incidents of more severe complications. The results remained steady across all platforms, showing 80.5% for Myval, 75.0% for Sapien, and 79.7% for Evolut series. Notably, the Myval series achieved the lowest recorded incidence of moderate aortic regurgitation at 1.6%, demonstrating its superior hemodynamic stability and performance post one year.
Insights on Small Aortic Annulus Performance
In a post-hoc analysis focusing on patients with a smaller aortic annulus, the results illustrated comparable one-year efficacy rates, with the Myval THV series achieving 91% compared to 89% for the Sapien series, with the Evolut series also at 91%.
A Reliable Option for Patients
These outstanding results solidify the Myval THV series’ position as a reliable and effective treatment option, sustaining both safety and performance for a variety of patient anatomies.
Professor Patrick W. Serruys, Chairman and Study Director of the LANDMARK Trial, expressed, "This trial continues to yield valuable insights into comparative valve performance, aiding in clinical decision-making tailored to patient needs. The data support ongoing discussions about personalized valve selection, enhancing patient care through informed choices regarding transcatheter devices."
Similarly, Professor Andreas Baumbach, the Global Principal Investigator, highlighted the unique potential of this study to serve as a benchmark across valve technologies under identical trial settings. Its consistent performance metrics provide clinicians with crucial insights for optimal treatment pathways, primarily as the patient demographic evolves to include younger, lower-risk patients.
Commitment to Innovation
Mr. Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, stated, "The continuation of performance data from the Myval THV series across diverse populations underscores its role as a next-generation therapy solution. At Meril, we prioritize developing clinically relevant solutions that significantly improve access to advanced heart care globally. These results lay a strong foundation for the Myval platform's broader adoption in varying healthcare environments."
Looking ahead, the LANDMARK trial will maintain patient follow-ups for a decade to assess long-term valve performance, stability, and echocardiographic outcomes.
About the LANDMARK Trial
The LANDMARK trial is hailed as a pivotal non-inferiority trial, directly comparing the Myval THV series with leading balloon-expandable and self-expandable options in managing aortic stenosis. Encompassing 768 patients across 31 sites in 16 countries, this trial sets precedence in transcatheter valve studies. Significant findings from both the 30-day primary endpoint and one-year results have been successfully published in renowned medical journals, reflecting the Myval series' competitive standing in the market.
About Meril Life Sciences
Meril Life Sciences is a global medical device innovator committed to enriching healthcare through advanced solutions. With operations in over 135 countries and dedicated subsidiaries spanning various continents, Meril focuses on developing cutting-edge technologies adhering to rigorous international quality standards. This commitment to excellence positions Meril at the forefront of transforming healthcare delivery worldwide.
Frequently Asked Questions
What is the LANDMARK trial?
The LANDMARK trial is a pivotal multicenter RCT evaluating the Myval THV series against other established transcatheter heart valves in patients with severe aortic stenosis.
What were the one-year outcomes reported for Myval THV?
The Myval THV series reported a composite efficacy of 87%, demonstrating strong performance compared to its competitors at one year.
What distinguishes Myval THV from other series?
Myval THV exhibited the lowest incidence of moderate aortic regurgitation and superior hemodynamic performance at one year, marking it as a significant choice for patients.
How many patients were included in the trial?
The LANDMARK trial included 768 patients across 31 international sites, making it a large-scale and robust comparative study.
What is the next step for the LANDMARK trial?
The trial will continue to follow patients for a decade to gather essential long-term data on valve performance and stability.
